OBJECTIVE: Despite significant psychosocial morbidity, there are few controlled trials of psychological support for people with brain tumor. This study evaluated the efficacy of the Making Sense of Brain Tumor (MSoBT) program, a home-based psychosocial intervention. DESIGN: A randomized controlled trial with a wait list condition METHODS:Fifty participants aged 17-82 years with brain tumor (54% benign) were randomly allocated to immediate treatment (n = 27) or a waitlist (n = 23). Measures included Montgomery-Asberg Depression Rating Scale (MADRS), McGill Quality of Life (MQOL) Questionnaire, Depression Anxiety Stress Scales (DASS) and Functional Assessment of Cancer Therapy-Brain (FACT-Br). The immediate treatment group received the 10-session MSoBT program, while the waitlist group received usual care for 10 weeks and were then re-assessed before receiving the MSoBT program. A 6-month post-intervention follow-up was conducted. RESULTS: Analysis of covariance adjusting for baseline functioning identified that the immediate treatment group reported significantly lower levels of depression on the MADRS (η(p)(2) = .19) and higher levels of existential well-being on the MQOL (η(p)(2) = .13) and functional well-being (η(p)(2) = .21) and global quality of life on the FACT-Br (η(p)(2) = .12) at post-assessment than the waitlist group. At 6-month follow-up participants reported significantly lower levels of depression and stress and higher existential well-being and quality of life relative to pre-intervention. CONCLUSIONS: The MSoBT program appears to have efficacy for enhancing psychological well-being and quality of life after brain tumor.
RCT Entities:
OBJECTIVE: Despite significant psychosocial morbidity, there are few controlled trials of psychological support for people with brain tumor. This study evaluated the efficacy of the Making Sense of Brain Tumor (MSoBT) program, a home-based psychosocial intervention. DESIGN: A randomized controlled trial with a wait list condition METHODS: Fifty participants aged 17-82 years with brain tumor (54% benign) were randomly allocated to immediate treatment (n = 27) or a waitlist (n = 23). Measures included Montgomery-Asberg Depression Rating Scale (MADRS), McGill Quality of Life (MQOL) Questionnaire, Depression Anxiety Stress Scales (DASS) and Functional Assessment of Cancer Therapy-Brain (FACT-Br). The immediate treatment group received the 10-session MSoBT program, while the waitlist group received usual care for 10 weeks and were then re-assessed before receiving the MSoBT program. A 6-month post-intervention follow-up was conducted. RESULTS: Analysis of covariance adjusting for baseline functioning identified that the immediate treatment group reported significantly lower levels of depression on the MADRS (η(p)(2) = .19) and higher levels of existential well-being on the MQOL (η(p)(2) = .13) and functional well-being (η(p)(2) = .21) and global quality of life on the FACT-Br (η(p)(2) = .12) at post-assessment than the waitlist group. At 6-month follow-up participants reported significantly lower levels of depression and stress and higher existential well-being and quality of life relative to pre-intervention. CONCLUSIONS: The MSoBT program appears to have efficacy for enhancing psychological well-being and quality of life after brain tumor.
Authors: Crystal L Park; James E Pustejovsky; Kelly Trevino; Allen C Sherman; Craig Esposito; Mark Berendsen; John M Salsman Journal: Cancer Date: 2019-04-29 Impact factor: 6.860
Authors: Sebastian Otto-Meyer; Jan Lumibao; Eugene Kim; Erik Ladomersky; Lijie Zhai; Kristen L Lauing; Denise M Scholtens; Frank Penedo; Christina Amidei; Rimas V Lukas; Derek A Wainwright Journal: Curr Opin Behav Sci Date: 2019-02-26
Authors: Chelsea Nicol; Tamara Ownsworth; Lee Cubis; William Nguyen; Matthew Foote; Mark B Pinkham Journal: J Cancer Surviv Date: 2019-07-17 Impact factor: 4.442
Authors: Ashlee R Loughan; Morgan Reid; Kelcie D Willis; Alexandria Davies; Rachel L Boutté; Sarah Barrett; Karen Lo Journal: J Neurooncol Date: 2022-04-08 Impact factor: 4.130
Authors: Anthony Byrne; Anna Torrens-Burton; Stephanie Sivell; Fabio Ynoe Moraes; Helen Bulbeck; Mark Bernstein; Annmarie Nelson; Helen Fielding Journal: Cochrane Database Syst Rev Date: 2022-01-06
Authors: Ashlee R Loughan; Kelcie D Willis; Sarah Ellen Braun; Gary Rodin; Autumn Lanoye; Alexandria E Davies; Dace Svikis; Suzanne Mazzeo; Mark Malkin; Leroy Thacker Journal: J Neurooncol Date: 2022-04-18 Impact factor: 4.506